Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 592

1.

Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: ex quo and quo vadimus?

Katsiki N, Perakakis N, Mantzoros C.

Metabolism. 2019 Jul 10. pii: S0026-0495(19)30142-8. doi: 10.1016/j.metabol.2019.07.009. [Epub ahead of print] No abstract available.

PMID:
31301336
2.

Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.

Farr OM, Upadhyay J, Rutagengwa C, DiPrisco B, Ranta Z, Adra A, Bapatla N, Douglas VP, Douglas KA, Nolen-Doerr E, Mathew H, Mantzoros CS.

Diabetes Obes Metab. 2019 Jul 7. doi: 10.1111/dom.13827. [Epub ahead of print]

PMID:
31282006
3.

Of mice and men: incretin actions in the central nervous system.

Farr OM, Pilitsi E, Mantzoros CS.

Metabolism. 2019 Jun 4. pii: S0026-0495(19)30107-6. doi: 10.1016/j.metabol.2019.05.013. [Epub ahead of print] Review.

PMID:
31173757
4.

Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?

Polyzos SA, Kountouras J, Mantzoros CS.

Metabolism. 2019 Jul;96:iii-v. doi: 10.1016/j.metabol.2019.05.006. Epub 2019 May 20. No abstract available.

PMID:
31121179
6.

Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross-over, randomized, double-blind, controlled inpatient physiology study.

Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Klapa MI, Candela M, Rampelli S, Lehoux S, Lázaro I, Sala-Vila A, Brigidi P, Cummings RD, Mantzoros CS.

Diabetes Obes Metab. 2019 May 14. doi: 10.1111/dom.13773. [Epub ahead of print]

PMID:
31087608
7.

Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.

Polyzos SA, Perakakis N, Mantzoros CS.

Metabolism. 2019 Jul;96:66-82. doi: 10.1016/j.metabol.2019.05.001. Epub 2019 May 6. Review.

PMID:
31071311
8.

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.

Katsiki N, Dimitriadis G, Hahalis G, Papanas N, Tentolouris N, Triposkiadis F, Tsimihodimos V, Tsioufis C, Mikhailidis DP, Mantzoros C.

Metabolism. 2019 Jul;96:92-100. doi: 10.1016/j.metabol.2019.04.008. Epub 2019 Apr 11.

PMID:
30980838
9.

Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.

Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS.

Curr Vasc Pharmacol. 2019 Apr 5. doi: 10.2174/1570161117666190405164313. [Epub ahead of print]

PMID:
30961499
10.

Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?

Boutari C, Polyzos SA, Mantzoros CS.

Metabolism. 2019 Jul;96:vi-xi. doi: 10.1016/j.metabol.2019.03.007. Epub 2019 Mar 22. No abstract available.

PMID:
30910448
11.

Beyond glycemic control: New guidance on cardio-renal protection.

Anastasilakis AD, Sternthal E, Mantzoros CS.

Metabolism. 2019 Feb 22. pii: S0026-0495(19)30046-0. doi: 10.1016/j.metabol.2019.02.004. [Epub ahead of print] No abstract available.

PMID:
30797784
12.

Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: A six-month, randomized, placebo-controlled, double-blind clinical trial.

Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Mathew H, Paschou SA, Perakakis N, Koniaris A, Kelesidis T, Mantzoros CS.

Diabetes Obes Metab. 2019 Jun;21(6):1487-1492. doi: 10.1111/dom.13655. Epub 2019 Mar 18.

PMID:
30724455
13.

Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?

Anastasilakis AD, Polyzos SA, Makras P, Douni E, Mantzoros CS.

Metabolism. 2019 Apr;93:100-102. doi: 10.1016/j.metabol.2019.01.013. Epub 2019 Jan 25. No abstract available.

PMID:
30690037
14.

Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction?

Katsiki N, Mantzoros C.

Metabolism. 2019 Apr;93:iii-v. doi: 10.1016/j.metabol.2019.01.005. Epub 2019 Jan 16. No abstract available.

PMID:
30659799
15.

Free Cortisol Is a More Accurate Marker for Adrenal Function and Does Not Correlate with Renal Function in Cirrhosis.

Theocharidou E, Giouleme O, Anastasiadis S, Markopoulou A, Pagourelias E, Vassiliadis T, Fotoglidis A, Agorastou P, Slavakis A, Balaska A, Kouskoura MG, Gossios TD, Karagiannis A, Mantzoros CS.

Dig Dis Sci. 2019 Jun;64(6):1686-1694. doi: 10.1007/s10620-019-5460-x. Epub 2019 Jan 19.

PMID:
30659471
16.

Obesity: seize the day, fight the fat.

Polyzos SA, Mantzoros CS.

Metabolism. 2019 Mar;92:1-5. doi: 10.1016/j.metabol.2018.12.011. Epub 2019 Jan 6. No abstract available.

PMID:
30625300
17.

Research developments in metabolism 2018.

Peradze N, Farr OM, Mantzoros CS.

Metabolism. 2019 Feb;91:70-79. doi: 10.1016/j.metabol.2018.11.011. Epub 2018 Nov 29. Review. No abstract available.

PMID:
30503805
18.

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.

Polyzos SA, Kountouras J, Mantzoros CS.

Metabolism. 2019 Mar;92:82-97. doi: 10.1016/j.metabol.2018.11.014. Epub 2018 Nov 29. Review.

PMID:
30502373
19.

Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls.

Anastasilakis AD, Koulaxis D, Upadhyay J, Pagkalidou E, Kefala N, Perakakis N, Polyzos SA, Economou F, Mantzoros CS.

Horm Metab Res. 2019 Feb;51(2):112-119. doi: 10.1055/a-0794-6163. Epub 2018 Nov 29.

PMID:
30497090
20.

GEOFFREY HARRIS PRIZE LECTURE 2018: Novel pathways regulating neuroendocrine function, energy homeostasis and metabolism in humans.

Papathanasiou AE, Nolen-Doerr E, Farr OM, Mantzoros CS.

Eur J Endocrinol. 2019 Feb 1;180(2):R59-R71. doi: 10.1530/EJE-18-0847. Review.

PMID:
30475221

Supplemental Content

Loading ...
Support Center